

Metastron Policy

Purpose

To describe the CVS Radiation Oncology External Policy for Metastron.

Scope

The scope of this document applies to CVS Health clients who have signed up for the CVS Radiation Oncology program under CVS Health Solutions. This document includes the external policy details for the Metastron policy.

Policy

Strontium Chloride Sr-89 (Metastron) Policy

Criteria for Initial Approval

CVS Health considers strontium chloride Sr-89 (Metastron) medically necessary for the relief of bone pain when *all* of the following criteria are met:

- A. The member has a malignant/cancer diagnosis; and
- B. The member has bone metastases.

CVS Health considers all other indications as experimental and investigational (for additional information, see Experimental and Investigational and Background sections).

Continuation of Therapy

CVS Health considers continuation of strontium chloride Sr-89 (Metastron) therapy medically necessary in members requesting reauthorization for an indication listed in Section I when there is no evidence of unacceptable toxicity while on the current regimen.

Procedure

Dosage and Administration

Strontium Chloride Sr-89 is supplied in a 5 mL vial containing 148 MBq, 4mCi as a single dose for intravenous administration.

The recommended dosing is as follows:

Relief of bone pain in painful skeletal metastases:

Strontium chloride Sr-89 is administered as 148 MBq, 4 mCi by slow intravenous injection (1-2 minutes). Alternatively, a dose of 1.5 - 2.2 MBq/kg, 40-60 μ Ci/kg body weight may be used. (MBq = megabecquerel (one mCi equals 37 MBq); mCi = milliCurie). Repeated administrations of strontium chloride Sr-89 should be based on an individual's response to therapy, current symptoms, and hematologic status, and are generally not recommended at intervals of less than 90 days. The individual dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Note: Metastron is no longer available commercially.

Source: QBioMed, 2020

Experimental and Investigational

CVS Health considers radiopharmaceuticals such as strontium chloride Sr-89 experimental and investigational for all other indications including the following (not an all-inclusive list):

- Use in members with cancer not involving the bone
- For controlling intractable hypoglycemia in persons with malignant insulinoma
- For incorporating into calcium phosphate to improve bone repair
- For pre-conditioning of mesenchymal stromal cell-derived extracellular vesicles in bone regeneration
- For supplementing on implant osseointegration in the presence of osteoporotic bone
- For treating beta-thalassemia-associated osteoporosis

References

The Metastron policy is based on the following references:

1. Abruzzese E, Iuliano F, Trawinska MM, Di Maio M. 153Sm: Its use in multiple myeloma and report of a clinical experience. *Expert Opin Investig Drugs*. 2008;17(9):1379-1387.
2. Agency for Healthcare Research and Quality (AHRQ). Management of cancer pain. Summary, Evidence Report/Technology Assessment No. 35. AHRQ Pub. No. 01-E033. Rockville, MD: AHRQ; January 2001.
3. Amato RJ, Hernandez-McClain J, Henary H. Bone-targeted therapy: Phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. *Am J Clin Oncol*. 2008;31(6):532-538.
4. American College of Radiology (ACR), American Society for Radiation Oncology (ASTRO). ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. [online publication]. Reston, VA: American College of Radiology (ACR); 2010.
5. Andronis L, Goranitis I, Bayliss S, Duarte R. Cost-effectiveness of treatments for the management of bone metastases: A systematic literature review. *Pharmacoeconomics*. 2018;36(3):301-322.
6. Andronis L, Goranitis I, Pirrie S, et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: Results from the TRAPEZE trial (ISRCTN 12808747). *BJU Int*. 2017;119(4):522-529.
7. Ashayeri E, Omogbehin A, Sridhar R, Shankar RA. Strontium 89 in the treatment of pain due to diffuse osseous metastases: A university hospital experience. *J Natl Med Assoc*. 2002;94(8):706-711.
8. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. *Radiother Oncol*. 2005;75(3):258-270.
9. Baziotis N, Yakoumakis E, Zissimopoulos A, et al. Strontium-89 chloride in the treatment of bone metastases from breast cancer. *Oncology*. 1998;55(5):377-381.
10. Bhardwaj A, Swe KMM, Sinha NK. Treatment for osteoporosis in people with beta-thalassaemia. *Cochrane Database Syst Rev*. 2023;5(5):CD010429.
11. Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of strontium89 in patients with endocrine-refractory carcinoma of the prostate metastatic to bone. Practice Guideline Report No. 3-6. Toronto, ON: Cancer Care Ontario (CCO); October 2001.
12. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: A systematic review. *Lancet Oncol*. 2005;6(6):392-400.
13. Giammarile F, Mognetti T, Resche I. Bone pain palliation with strontium-89 in cancer patients with bone metastases. *Q J Nucl Med*. 2001;45(1):78-83.
14. Handkiewicz-Junak D, Poeppel TD, Bodei L, et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. *Eur J Nucl Med Mol Imaging*. 2018;45(5):846-859.

15. Hansen DV, Holmes ER, Catton G, et al. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer. *Am Fam Physician*. 1993;47(8):1795-1800.
16. Hertel FC, da Silva AS, de Paula Sabino A, et al. Preconditioning methods to improve mesenchymal stromal cell-derived extracellular vesicles in bone regeneration -- A systematic review. *Biology (Basel)*. 2022;11(5):733.
17. Hu Z, Tian Y, Li W, et al. The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer*. 2020;28(7):3291-3301.
18. James N, Pirrie S, Pope A, et al. TRAPEZE: A randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. *Health Technol Assess*. 2016;20(53):1-288.
19. Lam MG, de Klerk JM, van Rijk PP, Zonnenberg BA. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. *Anticancer Agents Med Chem*. 2007;7(4):381-397.
20. Lee CK, Aeppli DM, Unger J, et al. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. *Am J Clin Oncol*. 1996;19(2):102-107.
21. Li R, Li D, Jia G, et al. Diagnostic performance of theranostic radionuclides used in transarterial radioembolization for liver cancer. *Front Oncol*. 2021;10:551622.
22. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. *Cancer Metastasis Rev*. 2006;25(4):669-675.
23. Lu W, Zhou Y, Yang H, et al. Efficacy of strontium supplementation on implant osseointegration under osteoporotic conditions: A systematic review. *J Prosthet Dent*. 2022;128(3):341-349.
24. McEwan AJ. Use of radionuclides for the palliation of bone metastases. *Semin Radiat Oncol*. 2000;10(2):103-114.
25. Naganuma A, Mayahara H, Morizane C, et al. Successful control of intractable hypoglycemia using radiopharmaceutical therapy with strontium-89 in a case with malignant insulinoma and bone metastases. *Jpn J Clin Oncol*. 2012;42(7):640-645.
26. National Collaborating Centre for Cancer. Prostate cancer: Diagnosis and treatment. London, UK: National Institute for Health and Care Excellence (NICE); January 2014.
27. National Comprehensive Cancer Network (NCCN). Bone cancer. NCCN Clinical Practice Guidelines in Oncology, Version 1.2024. Plymouth Meeting, PA: NCCN; August 2023.
28. National Comprehensive Cancer Network (NCCN). Prostate cancer. NCCN Clinical Practice Guidelines in Oncology, Version 4.2023. Plymouth Meeting, PA: NCCN; September 2023.
29. National Comprehensive Cancer Network (NCCN). Sr-89 (Strontium-89). NCCN Radiation Therapy Compendium. Plymouth Meeting, PA: NCCN; July 2023.
30. Nightengale B, Brune M, Blizzard SP, et al. Strontium chloride Sr 89 for treating pain from metastatic bone disease. *Am J Health Syst Pharm*. 1995;52(20):2189-2195.
31. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. *Semin Nucl Med*. 2010;40(2):89-104.

32. Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. *Eur J Nucl Med.* 1997;24(10):1210-1214.
33. Porter AT, McEwan AJB. Strontium-899 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer. Results of a randomized controlled trial. *Semin Oncol.* 1993;20 (3 Suppl 2):38-43.
34. QBioMed, Inc. Strontium chloride Sr-89 injection, USP therapeutic for intravenous administration. Prescribing Information. New York, NY: BioMed; revised January 2020.
35. Robinson RG, Preston DF, Baxter KG, et al. Clinical experience with strontium-89 in prostatic and breast cancer patients. *Semin Oncol.* 1993;20(3 Suppl 2):44-48.
36. Robinson RG, Preston DF, Schiefelbein M, et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. *JAMA.* 1995;274(5):420-424.
37. Roque I Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. *Cochrane Database Syst Rev.* 2011;(7):CD003347.
38. Roque M, Martinez MJ, Alonso-Coello P, et al. Radioisotopes for metastatic bone pain. *Cochrane Database Syst Rev.* 2003;(4):CD003347.
39. Santos AO, Ricciardi JBS, Pagnano R, et al. Knee radiosynovectomy with ¹⁵³Sm-hydroxyapatite compared to ⁹⁰Y-hydroxyapatite: Initial results of a prospective trial. *Ann Nucl Med.* 2021;35(2):232-240.
40. Saito AI, Inoue T, Kinoshita M, et al. Strontium-89 chloride delivery for painful bone metastases in patients with a history of prior irradiation. *Ir J Med Sci.* 2023;192(2):569-574.
41. Shen X, Fang K, Yie KHR, et al. High proportion strontium-doped micro-arc oxidation coatings enhance early osseointegration of titanium in osteoporosis by anti-oxidative stress pathway. *Bioact Mater.* 2021;10:405-419.
42. Sheng X, Li C, Wang Z, et al. Advanced applications of strontium-containing biomaterials in bone tissue engineering. *Mater Today Bio.* 2023;20:100636.
43. Siegel HJ, Luck JV Jr, Siegel ME. Advances in radionuclide therapeutics in orthopaedics. *J Am Acad Orthop Surg.* 2004;12(1):55-64.
44. Silberstein EB, Eugene L, Saenger SR. Painful osteoblastic metastases: The role of nuclear medicine. *Oncology (Huntingt).* 2001;15(2):157-163; discussion 167-170, 174.
45. Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. *Semin Nucl Med.* 2005;35(2):152-158.
46. Suzawa N, Yamakado K, Takaki H, et al. Complete regression of multiple painful bone metastases from hepatocellular carcinoma after administration of strontium-89 chloride. *Ann Nucl Med.* 2010;24(8):617-620.
47. Terrisse S, Karamouza E, Parker CC, et al; MORPHEP Collaborative Group. Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: A meta-analysis of individual patient data from randomized clinical trials. *JAMA Oncol.* 2020;6(2):206-216.
48. Tu SM, Lin SH. Current trials using bone-targeting agents in prostate cancer. *Cancer J.* 2008;14(1):35-39.

49. Tunio M, Al Asiri M, Al Hadab A, Bayoumi Y. Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: A meta-analysis of randomized controlled trials. *Drug Des Devel Ther.* 2015;9:5291-5299.
50. Yan M-D, Ou Y-J, Lin y-J, et al. Does the incorporation of strontium into calcium phosphate improve bone repair? A meta-analysis. *BMC Oral Health.* 2022;22(1):62.
51. Ye X, Sun D, Lou C. Comparison of the efficacy of strontium-89 chloride in treating bone metastasis of lung, breast, and prostate cancers. *J Cancer Res Ther.* 2018;14(Supplement):S36-S40.
52. Zenda S, Nakagami Y, Toshima M, et al. Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. *Int J Clin Oncol.* 2014;19(4):739-743.
53. Zustovich F, Pastorelli D. Therapeutic management of bone metastasis in prostate cancer: An update. *Expert Rev Anticancer Ther.* 2016;16(11):1199-1211.